Bacteremia

• CLINICAL_TRIALS withdrawal · 2025-07-24
  Clinical Trial Update: PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections [Phase 4]

  A Phase 4 trial comparing pipercillin/tazobactam against meropenem for AmpC-producing bloodstream infections has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2023-03-29
  Clinical Trial Update: Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia [Phase 4]

  A Phase 4 clinical trial on therapeutic drug monitoring and continuous infusion of beta-lactam antibiotics for bacteremia was withdrawn.

• CLINICAL_TRIALS withdrawal · 2022-05-19
  Clinical Trial Update: Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection [Phase 3]

  Phase 3 trial comparing ceftolozane-tazobactam to meropenem for ESBL/AmpC-producing Enterobacterales bacteremia was withdrawn.

• CLINICAL_TRIALS withdrawal · 2019-10-09
  Clinical Trial Update: Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria [Phase 2, Phase 3]

  A randomized-controlled trial evaluating a combination antibiotic for gram-negative infections (bacteremia and healthcare-associated pneumon…

• CLINICAL_TRIALS withdrawal · 2014-05-28
  Clinical Trial Update: A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. Epidermidis [Phase 1, Phase 2]

  The trial evaluating tolerability and early efficacy of the hLF1-11 peptide in bacteremia due to Staphylococcus epidermidis has been withdra…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS withdrawal · 2011-09-28
  Clinical Trial Update: Safety and Efficacy Study of CUBICIN (Daptomycin) Under Conditions of Actual Use

  A study evaluating the safety and efficacy of Cubicin (daptomycin) under real-use conditions has been withdrawn.